Broad Neutralizing Antibodies to Groups 1 and 2 Influenza HA
Exclusively Licensed
Invention type: Technology
/
Case number: #15049
The present invention provides antibodies (e.g., monoclonal antibodies, human antibodies, humanized antibodies, etc.), which bind to multiple influenza strains. Such antibodies are useful, for example, in the prophylaxis, treatment, diagnosis, and/or study of influenza.
Researchers
Ram Sasisekharan
/
Vidya Subramanian
/
Kannan Tharakaraman
/
Venkataramanan Soundararajan
/
Sasisekharan Raguram
/
Viswanathan Sasisekharan
Departments: School of Engineering
Technology Areas: Drug Discovery and Research Tools: Antibodies / Therapeutics: Proteins & Antibodies, Vaccines
Impact Areas: Healthy Living
-
agents for influenza neutralization
India | Published application -
agents for influenza neutralization
United States of America | Granted | 9,683,030 -
agents for influenza neutralization
Chile | Granted | 61,294 -
agents for influenza neutralization
Japan | Granted | 6,431,477 -
agents for influenza neutralization
Mexico | Granted | 378,749 -
agents for influenza neutralization
United States of America | Granted | 9,982,037 -
agents for influenza neutralization
Singapore | Pending -
agents for influenza neutralization
Canada | Granted | 2,871,160 -
agents for influenza neutralization
Hong Kong | Published application -
agents for influenza neutralization
United States of America | Granted | 10,538,578 -
agents for influenza neutralization
Singapore | Granted | 11,201,406,769 -
agents for influenza neutralization
Israel | Granted | 235,237 -
agents for influenza neutralization
Australia | Granted | 2,018,202,468 -
agents for influenza neutralization
Japan | Published application -
agents for influenza neutralization
United States of America | Granted | 10,947,300 -
agents for influenza neutralization
Korea (south) | Granted | 2,122,618
License this technology
Interested in this technology? Connect with our experienced licensing team to initiate the process.
Sign up for technology updates
Sign up now to receive the latest updates on cutting-edge technologies and innovations.